Non-Leveraged ETFs

Overview

The Direxion mRNA ETF (MSGR) provides exposure to companies that are leading the development and application of messenger RNA ("mRNA") technology.

Investment Objective

The Direxion mRNA ETF (MSGR) seeks investment results, before fees and expenses, that track the BITA Messenger RNA Technology Index (BMRNAIN), investing in U.S., Canadian and European companies that are leading the development of messenger RNA technology. There is no guarantee that the fund will achieve its stated investment objective.

Index Description

The BITA Messenger RNA Technology Index (BMRNAIN) provides exposure to the performance of companies, publicly listed in the United States, Canada and Europe, that are leading the development and application of messenger RNA ("mRNA") technology. mRNA is a single-stranded ribonucleic acid ("RNA") molecule that is complementary to one of the DNA strands of a gene. mRNA plays a vital role in protein synthesis in the human body, and mRNA technologies leverage this vital role to enable targeted cells to produce proteins that enable the body to fight or prevent a given disease. As an example, mRNA technology is the basis for certain COVID-19 vaccines. Eligible companies must meet certain conditions as specified by the Index Provider as well as market capitalization and liquidity requirements. Index constituents are weighted based on a modified free float market capitalization and reconstituted and rebalanced quarterly. One cannot directly invest in an index.

Index Construction

Initial Universe Criteria—Companies must satisfy at least one of the below conditions:

- Be involved in the commercialization of products and therapies based on Messenger RNA technology, or sister RNA technologies (Small Interfering RNA, Micro RNA)
- Be classified as a clinical stage biotechnology company, with focus in the development of products and therapies that leverage the messenger RNA technology
- Have a portfolio of active, approved, mRNA technology-focused clinical trials
- Have any granted, active patents, with demonstrated involvement of the messenger RNA technology

Final Universe Criteria—Companies must then satisfy a minimum thematic exposure of 50% based on revenue exposure: For this index, in order to calculate the thematic exposure score, the following criteria is applied (if a company satisfies more than one criteria, the largest exposure score applies):

- Companies deriving at least 50% of their revenue from the commercialization of products and therapies based on Messenger RNA technology, or sister RNA technologies (Small Interfering RNA, Micro RNA), are attributed a thematic exposure score of 100%
- Companies with a declared (evidenced on company headline communication) focus on the development and commercialization of mRNA technology based products and therapies are attributed a thematic exposure score of 80%
- Companies with a portfolio of active, approved, mRNA technology-focused clinical trials, representing at least 50% of the total number of active clinical trials launched by the company, are attributed a thematic exposure score of 80%
- Clinical-stage companies, with at least one active, approved, mRNA technology-focused clinical trial, are attributed a thematic exposure score of 50%
An investor should carefully consider a Fund’s investment objective, risks, charges, and expenses before investing. A Fund’s prospectus and summary prospectus contain this and other information about the Direxion Shares. To obtain a Fund’s prospectus and summary prospectus call 866-476-7523 or visit our website at direxion.com. A Fund’s prospectus and summary prospectus should be read carefully before investing.

CUSIP Identifiers have been provided by CUSIP Global Services, managed on behalf of the American Bankers Association by Standard and Poor’s Financial Services, LLC, and are not for use or dissemination in any manner that would serve as a substitute for a CUSIP service. The CUSIP Database, ©2011 American Bankers Association. “CUSIP” is a registered trademark of the American Bankers Association.

Shares of the Direxion Shares are bought and sold at market price (not NAV) and are not individually redeemed from a Fund. Market Price returns are based upon the midpoint of the bid/ask spread at 4:00 pm EST (when NAV is normally calculated) and do not represent the returns you would receive if you traded shares at other times. Brokerage commissions will reduce returns. Fund returns assume that dividends and capital gains distributions have been reinvested in the Fund at NAV. Some performance results reflect expense reimbursements or recoupments and fee waivers in effect during certain periods shown. Absent these reimbursements or recoupments and fee waivers, results would have been less favorable.

Direxion Shares ETF Risks – Investing involves risk including possible loss of principal. There is no guarantee the investment strategy will be successful. mRNA technology is a novel technology and the development of products or therapies based on mRNA technology has substantial clinical development and regulatory risks. mRNA technologies may also provide ineffective or may produce adverse effects. Negative perception of the efficacy, safety, or tolerability of such mRNA-based products or therapies could adversely affect a company and the general acceptance of mRNA technologies. Additional risks of the Fund include, but are not limited to, Index Correlation Risk, Index Strategy Risk, Currency Exchange Rate Risk, Depositary Receipt Risk, Foreign Securities Risk, Cash Transaction Risk, Tax Risk, and risks associated with the market capitalizations and sectors of the securities in which the Fund may invest. Please see the summary and full prospectuses for a more complete description of these and other risks of the Fund.

Distributor: Foreside Fund Services, LLC.